BioMarin Pharmaceutical Inc. Watch

from 8-K 49 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) $450,000,000 0.599% Senior Subordinated Convertible Notes Due 2024 Underwriting Agreement

from 8-K 48 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) 7,500,000 Shares of Common Stock (Par Value $0.001 Per Share) Underwriting Agreement

from 8-K 49 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) 8,500,000 Shares of Common Stock (Par Value $0.001 Per Share) Underwriting Agreement

from 8-K 39 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) 1,500,000 Shares of Common Stock (Par Value $0.001 Per Share) Underwriting Agreement

from 8-K 49 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) $340,000,000 0.75% Senior Subordinated Convertible Notes Due 2018 $340,000,000 1.50% Senior Subordinated Convertible Notes Due 2020 Underwriting Agreement

from 8-K 55 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) 6,500,000 Shares of Common Stock (Par Value $0.001 Per Share) Underwriting Agreement

from 8-K 46 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) $282,500,000 1.875% Senior Subordinated Convertible Notes Due 2017 Purchase Agreement

from 8-K 47 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) 9,000,000 Shares of Common Stock (Par Value $0.001 Per Share) Purchase Agreement

from 8-K 45 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) $150,000,000 2.5% Senior Subordinated Convertible Notes Due 2013 Purchase Agreement

from 8-K 27 pages Biomarin Pharmaceutical Inc. (A Delaware Corporation) 8,500,000 Shares of Common Stock (Par Value $0.001 Per Share) Purchase Agreement

from SC 13G 1 page Joint Filing Agreement Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated June 1, 2004, (The "Schedule 13g"), With Respect to the Common Stock, $0.001 Par Value Per Share, of Biomarin Pharmaceutical Inc. Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 3rd Day of August 2004. Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President Orbimed Capital LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member By: /S/ Samuel D. Isaly Name: Samuel D. Isaly

from SC 13G 1 page Joint Filing Agreement Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated June 1, 2004, (The "Schedule 13g"), With Respect to the Common Stock, $0.001 Par Value Per Share, of Biomarin Pharmaceutical Inc. Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 3rd Day of August 2004. Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President Orbimed Capital LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member By: /S/ Samuel D. Isaly Name: Samuel D. Isaly

from SC 13G 1 page Joint Filing Agreement Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated June 1, 2004, (The "Schedule 13g"), With Respect to the Common Stock, $0.001 Par Value Per Share, of Biomarin Pharmaceutical Inc. Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 3rd Day of August 2004. Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President Orbimed Capital LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member By: /S/ Samuel D. Isaly Name: Samuel D. Isaly

from SC 13G 1 page Joint Filing Agreement Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated June 1, 2004, (The "Schedule 13g"), With Respect to the Common Stock, $0.001 Par Value Per Share, of Biomarin Pharmaceutical Inc. Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 3rd Day of August 2004. Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President Orbimed Capital LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member By: /S/ Samuel D. Isaly Name: Samuel D. Isaly

from 8-K 46 pages Biomarin Pharmaceutical Inc. 7,500,000 Shares Common Stock ($0.001 Par Value) Underwriting Agreement

from POS AM 1 page Exhibit 1.3 First Amendment to Engagement Letter

from POS AM 1 page Underwriting agreement

from S-3MEF ~20 pages Underwriting agreement

from S-3/A ~20 pages Underwriting agreement

from POS AM ~50 pages Underwriting agreement